Citoprotective effects of erythropoietin


Cite item

Full Text

Abstract

This state-of-art lecture is dedicated to erythropoietin influence on not hemopoietic tissues, the opportunity of this mediator to decrease the expression of tissue damage at experimental hypoxia and ischemia

About the authors

Yu M Zakharov

References

  1. Захаров Ю.М. Молекулярные и клеточно-клеточные механизмы регуляции эритропоэза // Вестник РАМН. 2. 2000. 4-9.
  2. Захаров Ю.М. Роль обратных связей в регуляции эритропоэза // Российский физиолог. ж. им. Сеченова. 92. 9. 2006. 1033-1045.
  3. Захаров Ю.М. Черты информационной сигнализации, регулирующей гемопоэз // Вестник РАМН. 6. 2002. 58-60.
  4. Захаров Ю.М. Чувствительность клеток к кислороду и продукция эритропоэтина // Росс. физиолог. ж. им. И.М. Сеченова. 91. 2005. 9. 993-1004.
  5. Захаров Ю.М. Неэритропоэтические функции эритропоэтина // Росс. физиол. ж. им. И.М. Сеченова. 93. 6 2007. 592-608.
  6. Маслов Л.Н., Лишманов Ю.Б., Соленкова Н.В. Адаптация миокарда к ишемии //Успехи физиол. наук. 37. 3. 2006. 25-41.
  7. Тимошенко Т.Е., Барабанова В.В. Влияние эритропоэтина на сократительную активность сосудов при экспериментальной почечной недостаточности: В кн.: Эритропоэтин в лечении хронической почечной недостаточности. Мед. информ. агентство. СПб. 1995. 141-151.
  8. Тимошенко Т.Е., Барабанова В.В., Белоусова Е.И и др. Роль структурно-функциональных особенностей сосудистой стенки в механизме действия эритропоэтина на активность гладкомышечных клеток // Российский физиологический журнал им. Сеченова. 79. 7. 1993. 115-117.
  9. Anagnostou A., Lee E.S., Kessimian N. et al. Erythropoietin has a mitogenic and positive chemotactic effect of endothelian cells // PNAS. 87. 1990. 5978-5982.
  10. Anagnostou A., Liu Z., Steiner M. et al. Erythropoietin receptor mRNA expression in human endothelial cells. PNAS. 91. 1994. 3974-3978.
  11. Bahlmann FH, de Groot K, Spandau J-M. et al. Erythropoietin regulates endothelial progenitor cell // Blood. 2004. 103:921-926.
  12. Beg AA., Baltimore D., An essential role for NF-kB in preventing TNF-α-induced cell death // Science. 1996. 274:782-784.
  13. Bruce A.J. et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptor. Nat.Med. 2. 1996. 788-794.
  14. Brines M. L., Ghezzi P., Keenan S. et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury // PNAS. 97. 2000. 19. 10526-10531.
  15. Brines M., Grasso G., Fiordaliso F. et al. Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor // PNAS. 2004. 101:14907-14912.
  16. Cai Z., Gregg L., Semenza G.L. Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion Injury. Curculation. 109(17). 2004. 2050-2053
  17. Cai Z., Manalo D.J., Wei G. et al. Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion Injury. Circulation. 108. 2003. 79-85.
  18. Calvillo L., Latini R., Kajstura J. et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling // PNAS. 15.04.2003.4802-4806.
  19. Carlini R.G., Reyes A.A., Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 47. 1995. 740-745.
  20. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt l and mitochondrial modulation of cysteine proteases. Circ. Res. 106. 2002. 2973-2979.
  21. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13. 1999. 2905-2927.
  22. Digicaylioglu M.A. and Lipton S.A. Erythropoietin-edited neuroprotection involves cross-talk between Jak2 and Nf-κB signaling cascades. Nature. 412. 2001.641-647.
  23. Digiсaylioglu M., Bichet S., Marti Н.Н., et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain // PNAS. 92. 1995. 3717-3720.
  24. Downey J.M., Cohen M.V. Signal transduction in ischemiс preconditioning. Adv. Exp. Med.Biol. 36. 1997. 39-55.
  25. Fantacci M., Bianciardi P., Caretti A. et al. Carbomylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia // PNAS. 103. 2006.17531-17536.
  26. Ferrario M., Massa M., Rosti V. et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction // European Heart J. 2007.28(15):1805-1813.
  27. Fiordaliso F., Chimenti S., Staszewsky L. et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury // PNAS. 2005. 8:102(6): 2046-2051.
  28. Ficher J.M. Erythropoietin: Physiology and Pharmacology Update. Exp. Biol. Med. 228. 2003. 1-14.
  29. Fontaine V. et al. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor I and TNF receptor 2 // J. Neurosci. 22. 2002. RC216.
  30. Gregory T. et al. CATA-1 and erythropoietin cooperate no promote erythroid cell survival by regulating bcl-xL expression. Blood. 94. 1999. 87-96.
  31. Haller H., Christel C., Dannenberg L. et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996. 50:481.
  32. Helschen C., Aicher A., Lehmann R. et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization // Blood. 2003. 102:1340-1346.
  33. Heidenreich S., K.-H.Rahn, Zidek. Erythropoietin induced contraction of isolated renal small resistance vessels. Abstr. XXVII Congr. Europ. Renal Association. Viena. 1990. 246.
  34. Javadov S.A., Clarke S., Das M. Ischemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J. Physiol. 549. 2. 2003. 513-524.
  35. Juhaszova M., Zoron DB., Kim SH. et al. Glycogen synthase kinase-3 mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore // JClin Invest. 113. 2004. 1535-1549.
  36. Juul S.E., Stallings S.A., Christensen R.D. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res. Nov; 1999. 46(5):543-547.
  37. Juul S.E, McPherson R.J., Farrell F.X. et al. Erythropoietin concentration in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate. 85. 2004. 138-144.
  38. Lando D., Jeffrey J., Gorman, Murray L., Whitelaw and Daniel J., Peet. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur. J. Biochem. 270. 2003. 781-790.
  39. Marchetti L.,Klein M.,Schlett K. et al. Tumor necrosis factor (TNF) - mediated neuroprotection against glutamate - induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation // J. Biol. Chem. 279. 2004. 32869-32881.
  40. Meydan N. et al. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature. 379. 1996. 645-648.
  41. Moon C., Krawczyk M., Ahn D. et al. Erythropoietin reduces myocardial infarction and left ventricular functional dec line after coronary artery ligation in rats // PNAS. V. 100. 2003. 11612-11617.
  42. Moon C., Krawczyk M., Paik D. et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties // J. Pharmacol Exp Ther. 2005. 316:999-1005.
  43. Ostadalova I, Ostadal B, Jarkovska D, et al. Ischemic preconditioning in chronically hypoxic rat heart. Pediatr Res. 2002. 52:561-567.
  44. O'Neill LA., Kaltschmidt C. NF-k B: a crucial transcription factor for glial and neuronal cell function // Trends neurosci. 1997. 20; 252-258.
  45. Parsa C.J., Kim J., Riel R.U. et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart // J. Biological. 279. 20. 2004. 20655-20662.
  46. Parsa C.J., Matsumoto A., Kim J. et al. A novel protective effects of erythropoietin in the infarcted heart // J. Clin. investig. 2003. 112:999-1007.
  47. Post H., Heusch G. Ischemic preconditioning. Experimental facts and clinical perspective. Minerva Cardioangiol. 50. 6. 2002. 569-605.
  48. Raffiee P., Shi Y., Kong X., et al. Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection. Circulation. 106. 2002. 239-245.
  49. Ribatti BD., Presta M., Vacca A. et al. Human Erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cell and stimulates neovascularization in vivo // Blood. 93. 8. 1999. 2627-2636.
  50. Raine A.E. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy // Lancet. 1988. 1:97-99.
  51. Semenza G.L HIF-1 and tumor progression: pathophysiology and therapeutics. Trends. Mol. Med. 8 (4 Suppl). 2002. 62-67.
  52. Shi Y., Rafiee P., Su J., Pritchard KA Jr. et alAcute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels // Basis Res Cardiol. 2004. 99:173-182.
  53. Silva M., Benito A., Sanz C. et al. Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines. The J. of Biol. Chemi. 274. 32. 22165-22169. 1999.
  54. Siren A.-L.,Fratelli M.,Brines M. et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. PNAS. 27. 2001. 4044-4049.
  55. Taoufik E., Petit E., Divoux D. et al. TNE receptor I sensitizes neurons to erythropoietin - and VEGF-mediated neuroprotection after ischemic and excitotoxic injury // PNAS. 105(16). 2008. 6185-6190.
  56. Vogel V., Kramer HJ., Backer A. et al. Effects of erythropoietin on endothelin-1 synthesis and cellular calcium messenger system in vascular endothelial cell. Am J. Hypertens. 1997. 10:289.
  57. Vaziri N.D., Zhou X.J., Smith J. et al. In vivo and in vitro pressor effects of erythropoietin in rats //Americ. Physiological society. 1995. 95: 838-845.
  58. Wang CY., Mayo MW., Baldwin AS., Jr TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB // Science. 1996. 274:784-787.
  59. Wang CY., Mayo MW., Korneluk RG. et al. Jr. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8-activation // Science. 1998. 281:1680-1683.
  60. Wen T.C., Sadamoto Y., Tanaka J. et al. Erythropoietin protect neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J.Neurosci.Res. 67. 2002.795-803.
  61. Wu H., Lee S.H. Gao J., Liu X. et al.Development (Cambridg, U.K.). 126. 1999. 3597-3605.
  62. Yamaji R.,Okada T.,Moriya M. et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur.J. Biochem. 239. 1996. 494-500.
  63. Ytrehus K.,Liu J.,Downey J.M.,Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. 266. 1994. 41145-41152.
  64. Yu X., Lin, C.S., Costantini F., Noguchi C.T. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin null mouse. Blood. 98. 2001. 475-477.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies